Skip to main content
. 2019 Sep 3;7(9):1189–1197. doi: 10.1177/2050640619873784

Figure 3.

Figure 3.

(a) Rates of clinical remission at week 22 by quartiles (Qs) of vedolizumab trough level (VTL) at week 14 (p < 0.001); (b) rates of clinical remission at week 54 by Qs of VTL at week 14 (p = 0.0076); (c) rates of mucosal healing (MH) by Qs of VTL at week 14 (p = 0.013).